Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4329-4340

  Ruiz, Miguel A ^a   Álvarez, Enrique ^b   Carrasco, Jose L ^c   Olivares, José M ^d   Pérez, María ^e   Rejas, Javier ^e  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL DO MEIXOEIRO   (Spain)

^e PFIZER INC   (United States)

Author keywords

Generalized anxiety disorders; Latent curve analysis; Pregabalin; Sleep disturbances; Usual care

Indexed keywords

PREGABALIN; ANXIOLYTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT CARE; PROSPECTIVE STUDY; SCORING SYSTEM; SELF REPORT; SLEEP DISORDER; YOUNG ADULT; ANXIETY DISORDERS; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; SLEEP WAKE DISORDERS; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTPATIENTS; PREGABALIN; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SLEEP WAKE DISORDERS; TREATMENT OUTCOME;

EID: 84939863642     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S88238     Document Type: Article

References (40)

1. Alonso J, Angermeyer MC, Bernert S, et al; ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109(Suppl 420):21–27.
2. Ansseau M, Fischler B, Dierick M, Mignon A, Leyman S. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry. 2005;20:229–235.
3. Wetherell JL, Kim DS, Lindamer LA, et al. Anxiety disorders in a public mental health system: clinical characteristics and service use patterns. J Affect Disord. 2007;104:179–183.
4. Haro JM, Palacín C, Vilagut G, et al. Prevalencia de los trastornos mentales y factores asociados: resultados del estudio ESEMeD-España. Med Clin (Bar). 2006;126:445–451.
5. Kessler RC, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med. 2005;35:1073–1082.
6. van Mill JG, Hoogendijk WJ, Vogelzangs N, van Dyck R, Penninx BW. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J Clin Psychiatry. 2010;71: 239–246.
7. Gould RA, Otto MW, Pollack MH, Yap L. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behav Ther. 1997;28:285–305.
8. Martin JLT, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trial. J Psychopharmacol. 2001;21:774–782.
9. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal: prospective study of clorazepate and buspirone. Arch Gen Psychiatr. 1988;45:455–450.
10. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:403–439.
11. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care. Int J Psych Clin Prac. 2012;16:77–84.
12. Keck PE, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry. 2006;67:8–15.
13. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 outpatients with bipolar disorder. Am J Psychiatry. 2004;158:420–426.
14. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65:1219–1222.
15. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240–249.
16. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022–1030.
17. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771–782.
18. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29: 26–48.
19. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28:187–193.
20. de Haas S, Otte A, de Weerd A, van Erp G, Cohen A, van Gerven J. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med. 2005;3:473–478.
21. Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or post-herpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin. 2010;26:2411–2419.
22. Rubio G, Bobes J, Cervera G, et al. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur Addict Res. 2011;17:262–270.
23. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235–259.
24. Bollu V, Bushmakin AG, Cappelleri JC, Chen Ch, Feltner D, Wittchen HU. Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. Eur J Psychiatr. 2010;24:18–27.
25. Montgomery SA, Herman BK, Schweizer E, Mandel FS. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol. 2009;24:214–222.
26. Simes RJ. Clinical trials and “real-world” medicine. Trial evidence best informs real-world medicine when it is relevant to the clinical problem. Med J Aust. 2002;177:410–411.
27. Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol. 2002; 16:925–936.
28. Roth T, Arnold LM, Garcia-Borreguero D, et al. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med Rev. 2014;18:261–271.
29. Álvarez E, Carrasco JL, Olivares JM, Vilardaga I, López-Gómez V, Pérez M. Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: findings from the observational ADAN study. Clin Pract Epidemiol Men Health. 2012;8:158–168.
30. Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012;27:142–150.
31. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiat. 1969;3: 76–79.
32. Lobo A, Chamorro L, Luque A, Dal-Ré R, Badia X, Baró E; Grupo de Validación en Español de Escalas Psicométricas (GVEEP). Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales. Med Clin (Barc). 2002;118:493–499.
33. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psycopharmacology. Rockville, MD: National Institute for Mental Health; 1976:218–222.
34. Baron RM, Keny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Personal Soc Psychol. 1986;51:1173–1182.
35. Bollen KA, Curran PJ. Latent Curve Models. A structural equation perspective. Hoboken, NJ: John Wiley & Sons; 2006.
36. Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Method. 1982;13:290–312.
37. Soper DS. Sobel Test Calculator for the significance of mediation (Online Software). Available from: http://www.danielsoper.com/statcalc3. Accessed April 2012.
38. Bollu V, Bushmakin AG, Cappelleri JC. Psychometric evaluation of the medical outcomes study sleep scale in patients with generalized anxiety disorder. Qual Life Res. 2008;17:A114(abstract 1591).
39. Wittchen HU, Prieto R, Emir B, Donevan S. Comparative Effects of Pregabalin in Anxiety and Sleep Disturbance: Results of a Path Analysis. In: 19th European Congress of Psychiaty; March 12–15, 2011;Vienna, Austria.
40. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65:551–562.